{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:50:15Z","timestamp":1792090215238,"version":"4.4.0"},"reference-count":62,"publisher":"American Association for the Advancement of Science (AAAS)","content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Macrophages are crucial components of the tumor microenvironment (TME). Triggering receptor expressed on myeloid cells 2-positive (TREM2\n                    <jats:sup>+<\/jats:sup>\n                    ) macrophages have recently emerged as potent pro-tumor progress players in several cancers. However, the heterogeneity and tumor-promoting mechanisms of macrophages especially TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophages in ICC remain systematically unexplored. Therefore, this study aimed to systematically elucidate the heterogeneity of macrophages in ICC, with a specific focus on the pro-tumor role of TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophages.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We collected tumor tissues, adjacent nontumor tissues, and tumor-adjacent border tissues from 16 ICC patients. These samples were subjected to single-cell RNA sequencing and spatial transcriptomic sequencing, followed by comprehensive analysis. The findings were further validated through flow cytometry, immunohistochemistry, multiplex immunofluorescence, and in\u00a0vitro cellular assays. Furthermore, we established an ICC model using genetically engineered (\n                    <jats:italic toggle=\"yes\">\n                      Trem2\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    <\/jats:italic>\n                    ) mice as a validation cohort to corroborate the discoveries from human samples.\n                    <jats:bold>Results:<\/jats:bold>\n                    Macrophages are important prognostic factors in ICC, with functional heterogeneity. TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophages in tumor tissues promote immune suppression by exhausting CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and inducing the generation of regulatory T cells to produce. At the tumor border region, TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophages enhance ICC invasion via the urokinase-type plasminogen activator\u2013urokinase-type plasminogen activator receptor axis and induce hepatic stellate cell conversion to myofibroblastic cancer-associated fibroblast, forming a physical immune barrier that impedes CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration in tumor tissues. TIMD4\n                    <jats:sup>+<\/jats:sup>\n                    macrophages in adjacent tissues also suppress CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell function. Combining anti-Trem2 and anti-Timd4 with anti-Pd-1 antibodies significantly improved treatment outcomes in the ICC mice.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    TREM2\n                    <jats:sup>+<\/jats:sup>\n                    and TIMD4\n                    <jats:sup>+<\/jats:sup>\n                    macrophages are key regulators of the immunosuppressive TME in ICC. Targeting Trem2 and Timd4 enhances the effectiveness of anti-Pd-1 therapy in ICC mouse models.\n                  <\/jats:p>","DOI":"10.34133\/cancomm.0056","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:30:20Z","timestamp":1789021820000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Targeting TREM2\n                    <sup>+<\/sup>\n                    and TIMD4\n                    <sup>+<\/sup>\n                    Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma"],"prefix":"10.34133","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-4970","authenticated-orcid":false,"given":"Yao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing Drum Tower Hospital, \rThe Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing Drum Tower Hospital, \rThe Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangrui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing Drum Tower Hospital, \rThe Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, \rNaval Medical University, Shanghai, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12627"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"issue":"2","key":"e_1_3_4_4_2","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris D","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00741-4"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00547-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12034"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.017"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.026"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.030"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12345"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.003"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0299"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.032"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01475-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1631-3"},{"issue":"5","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris HA","year":"2024","unstructured":"Burris HA III, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc J-F, Li J, Bachini M, \u017botkiewicz M, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626\u2013635.","journal-title":"Lancet Oncol"},{"issue":"10391","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen HJ, Chan SL, Ozaka M, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u20131865.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study","volume":"8","author":"Shi GM","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023;8(1):106.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.12.006"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.037"},{"issue":"7","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2021-324109","article-title":"GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity","volume":"71","author":"Ruffolo LI","year":"2022","unstructured":"Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022;71(7):1386\u20131398.","journal-title":"Gut"},{"issue":"3","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001946","article-title":"Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3","volume":"9","author":"Zhou Z","year":"2021","unstructured":"Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, Luo C, Zhou J, Fan J, Zhou S. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer. 2021;9(3): Article e001946.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","article-title":"Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer","volume":"6","author":"Liu H","year":"2021","unstructured":"Liu H, Liang Z, Zhou C, Zeng Z, Wang F, Hu T, He X, Wu X, Wu X, Lan P. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):144.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/2159-8290.CD-23-0601","article-title":"p53 gain-of-function mutation induces metastasis via BRD4-dependent CSF-1 expression","volume":"13","author":"Efe G","year":"2023","unstructured":"Efe G, Dunbar KJ, Sugiura K, Cunningham K, Carcamo S, Karaiskos S, Tang Q, Cruz-Acu\u00f1a R, Resnick-Silverman L, Peura J, et al. p53 gain-of-function mutation induces metastasis via BRD4-dependent CSF-1 expression. Cancer Discov. 2023;13(12):2632\u20132651.","journal-title":"Cancer Discov"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001185"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.001"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.013"},{"issue":"1","key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41392-020-00383-5","article-title":"Therapeutic utility of immunosuppressive TREM2+ macrophages: An important step forward in potentiating the immune checkpoint inhibitors","volume":"5","author":"Alkan FK","year":"2020","unstructured":"Alkan FK, Korkaya H. Therapeutic utility of immunosuppressive TREM2+ macrophages: An important step forward in potentiating the immune checkpoint inhibitors. Signal Transduct Target Ther. 2020;5(1):264.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.006"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01631-w"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.002"},{"issue":"11","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002375","article-title":"A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis","volume":"7","author":"Beham AW","year":"2011","unstructured":"Beham AW, Puellmann K, Laird R, Fuchs T, Streich R, Breysach C, Raddatz D, Oniga S, Peccerella T, Findeisen P, et al. A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis. PLOS Pathog. 2011;7(11): Article e1002375.","journal-title":"PLOS Pathog"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90304-9"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00004.2011"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090148"},{"issue":"1","key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland SA","year":"2018","unstructured":"MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, Manuel J, Khuu N, Echeverri J, Linares I, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. 2018;9(1):4383.","journal-title":"Nat Commun"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01298-3"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.04.003"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.02.021"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.11"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.064"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2292"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1219179"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01267-2"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.032"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx237"},{"issue":"1","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-020-00275-8","article-title":"Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: Functional and clinical significance","volume":"5","author":"Hu HF","year":"2020","unstructured":"Hu HF, Xu WW, Zhang WX, Yan X, Li YJ, Li B, He QY. Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: Functional and clinical significance. Signal Transduct Target Ther. 2020;5(1):271.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41392-021-00579-3","article-title":"Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3","volume":"6","author":"Sun H","year":"2021","unstructured":"Sun H, Wang C, Hu B, Gao X, Zou T, Luo Q, Chen M, Fu Y, Sheng Y, Zhang K, et al. Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3. Signal Transduct Target Ther. 2021;6(1):187.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.039"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.03.012"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.011"},{"issue":"4","key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: Insights from single-cell analysis","volume":"20","author":"Leun AM","year":"2020","unstructured":"van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human cancer: Insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218\u2013232.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02345-0"},{"key":"e_1_3_4_57_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abk0957","article-title":"BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors","volume":"7","author":"Itahashi K","year":"2022","unstructured":"Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, Watanabe S, Goto Y, Suzuki J, Aokage K, et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022;7: Article eabk0957.","journal-title":"Sci Immunol"},{"key":"e_1_3_4_58_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak MA","year":"2023","unstructured":"Stanczak MA, L\u00e4ubli H. Siglec receptors as new immune checkpoints in cancer. Mol Asp Med. 2023;90: Article 101112.","journal-title":"Mol Asp Med"},{"issue":"10","key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1172\/JCI25673","article-title":"VSIG4, a B7 family-related protein, is a negative regulator of T cell activation","volume":"116","author":"Vogt L","year":"2006","unstructured":"Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I, et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest. 2006;116(10):2817\u20132826.","journal-title":"J Clin Invest"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg1955"},{"key":"e_1_3_4_61_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1834","article-title":"The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers","volume":"16","author":"Voissi\u00e8re A","year":"2024","unstructured":"Voissi\u00e8re A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, et al. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med. 2024;16: Article eadd1834.","journal-title":"Sci Transl Med"},{"issue":"1","key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1038\/s41467-018-07685-x","article-title":"CSF1R regulates the dendritic cell pool size in adult mice via embryo-derived tissue-resident macrophages","volume":"9","author":"Percin GI","year":"2018","unstructured":"Percin GI, Eitler J, Kranz A, Fu J, Pollard JW, Naumann R, Waskow C. CSF1R regulates the dendritic cell pool size in adult mice via embryo-derived tissue-resident macrophages. Nat Commun. 2018;9(1):5279.","journal-title":"Nat Commun"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.013"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/cancomm.0056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:08:56Z","timestamp":1792087736000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/cancomm.0056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":62,"alternative-id":["10.34133\/cancomm.0056"],"URL":"https:\/\/doi.org\/10.34133\/cancomm.0056","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2025-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0056"}}